{"id":"https://openalex.org/W4379979765","doi":"https://doi.org/10.1002/hon.3164_343","title":"Initial results of a multicenter phase 2 study of venetoclax in combination with R\u2010CHOP (VR\u2010CHOP) for patients with Richter Syndrome","display_name":"Initial results of a multicenter phase 2 study of venetoclax in combination with R\u2010CHOP (VR\u2010CHOP) for patients with Richter Syndrome","publication_year":2023,"publication_date":"2023-06-01","ids":{"openalex":"https://openalex.org/W4379979765","doi":"https://doi.org/10.1002/hon.3164_343","pmid":"https://pubmed.ncbi.nlm.nih.gov/39112211"},"language":"en","primary_location":{"id":"doi:10.1002/hon.3164_343","doi":"https://doi.org/10.1002/hon.3164_343","is_oa":true,"landing_page_url":"https://doi.org/10.1002/hon.3164_343","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3164_343","source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3164_343","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. S. Davids","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":null,"display_name":"K. A. Rogers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. A. Rogers","raw_affiliation_strings":["The Ohio State University, Columbus, Ohio, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Ohio State University, Columbus, Ohio, USA","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021380291","display_name":"Nitin Jain","orcid":"https://orcid.org/0000-0003-0114-8384","observed_orcids":["https://orcid.org/0000-0003-0114-8384"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"N. Jain","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, Texas, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, Texas, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010499534","display_name":"Svitlana Tyekucheva","orcid":"https://orcid.org/0000-0002-3119-6507","observed_orcids":["https://orcid.org/0000-0002-3119-6507"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Tyekucheva","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101914862","display_name":"Yi Lin Ren","orcid":"https://orcid.org/0000-0001-6004-4636","observed_orcids":["https://orcid.org/0000-0001-6004-4636"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Y. Ren","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":null,"display_name":"C. Carey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Carey","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021158149","display_name":"Josie S. Montegaard","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Montegaard","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078018977","display_name":"Michelle Hajdenberg","orcid":"https://orcid.org/0000-0002-8721-0021","observed_orcids":["https://orcid.org/0000-0002-8721-0021"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Hajdenberg","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069318096","display_name":"Christine E. Ryan","orcid":"https://orcid.org/0000-0003-2588-1943","observed_orcids":["https://orcid.org/0000-0003-2588-1943"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. E. Ryan","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065588144","display_name":"Reid W. Merryman","orcid":"https://orcid.org/0000-0002-6360-3234","observed_orcids":["https://orcid.org/0000-0002-6360-3234"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Merryman","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017446407","display_name":"Austin Injae Kim","orcid":"https://orcid.org/0000-0003-1039-0658","observed_orcids":["https://orcid.org/0000-0003-1039-0658","https://orcid.org/0000-0002-9675-9374"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Kim","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088077600","display_name":"Jennifer Leigh Crombie","orcid":"https://orcid.org/0000-0003-3445-5129","observed_orcids":["https://orcid.org/0000-0003-3445-5129"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Crombie","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037526878","display_name":"Caron Alyce Jacobson","orcid":"https://orcid.org/0000-0002-0180-0654","observed_orcids":["https://orcid.org/0000-0002-0180-0654"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. A. Jacobson","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085801543","display_name":"Ann Steward LaCasce","orcid":"https://orcid.org/0000-0001-7349-0176","observed_orcids":["https://orcid.org/0000-0001-7349-0176"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. S. LaCasce","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101930428","display_name":"David Christopher Fisher","orcid":"https://orcid.org/0000-0001-6915-8584","observed_orcids":["https://orcid.org/0000-0001-6915-8584"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. C. Fisher","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055037645","display_name":"Inhye E. Ahn","orcid":"https://orcid.org/0000-0003-3717-287X","observed_orcids":["https://orcid.org/0000-0003-3717-287X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"I. E. Ahn","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046770086","display_name":"Erin Michelle Parry","orcid":"https://orcid.org/0000-0002-3382-9769","observed_orcids":["https://orcid.org/0000-0002-3382-9769"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. M. Parry","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016570475","display_name":"Jennifer R. Brown","orcid":"https://orcid.org/0000-0003-2040-4961","observed_orcids":["https://orcid.org/0000-0003-2040-4961"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. R. Brown","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5080883357","display_name":"Philip A. Thompson","orcid":"https://orcid.org/0000-0003-2086-6031","observed_orcids":["https://orcid.org/0000-0003-2086-6031"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. A. Thompson","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, Texas, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, Texas, USA","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4220,"currency":"USD","value_usd":4220},"apc_paid":null,"fwci":3.9839,"has_fulltext":false,"cited_by_count":24,"citation_normalized_percentile":{"value":0.95130277,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"41","issue":"S2","first_page":"466","last_page":"468"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/richter-syndrome","display_name":"Richter syndrome","score":0.8709999918937683},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.9850000143051147},{"id":"https://openalex.org/keywords/r-chop","display_name":"R-CHOP","score":0.9639999866485596},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.777999997138977},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.902999997138977},{"id":"https://openalex.org/keywords/g-csf-support","display_name":"G-CSF support","score":0.6899999976158142},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.6430000066757202},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.4560000002384186},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.5389999747276306},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6100000143051147},{"id":"https://openalex.org/keywords/allogeneic-hematopoietic-stem-cell-transplantation","display_name":"allogeneic hematopoietic stem cell transplantation","score":0.7870000004768372},{"id":"https://openalex.org/keywords/17p-deletion","display_name":"17p deletion","score":0.6200000047683716},{"id":"https://openalex.org/keywords/tp53-mutation","display_name":"TP53 mutation","score":0.9340000152587891}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7522170543670654},{"id":"https://openalex.org/C2779725641","wikidata":"https://www.wikidata.org/wiki/Q1076228","display_name":"CHOP","level":3,"score":0.6060415506362915},{"id":"https://openalex.org/C2780790343","wikidata":"https://www.wikidata.org/wiki/Q5090610","display_name":"Chemoimmunotherapy","level":4,"score":0.5912238955497742},{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.5705273747444153},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.5253008008003235},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5150408744812012},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.43551111221313477},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4208694398403168},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4069218039512634},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.34337830543518066},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3400347828865051},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.3308912515640259},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.28790056705474854},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.18963715434074402},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.11510449647903442}],"mesh":[{"descriptor_ui":"D003226","descriptor_name":"Congresses as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008223","descriptor_name":"Lymphoma","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D013557","descriptor_name":"Switzerland","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/hon.3164_343","doi":"https://doi.org/10.1002/hon.3164_343","is_oa":true,"landing_page_url":"https://doi.org/10.1002/hon.3164_343","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3164_343","source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"},{"id":"pmid:39112211","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39112211","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological oncology","raw_type":"Congress"}],"best_oa_location":{"id":"doi:10.1002/hon.3164_343","doi":"https://doi.org/10.1002/hon.3164_343","is_oa":true,"landing_page_url":"https://doi.org/10.1002/hon.3164_343","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3164_343","source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":false},"content_urls":{"pdf":"https://content.openalex.org/works/W4379979765.pdf"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3032450706","https://openalex.org/W2950535635","https://openalex.org/W3213619356","https://openalex.org/W3217186366","https://openalex.org/W4283322658","https://openalex.org/W7093121600","https://openalex.org/W4411393484","https://openalex.org/W7203643217","https://openalex.org/W4393217506","https://openalex.org/W4405372161"],"abstract_inverted_index":{"Introduction:":[0],"We":[1,47,105],"previously":[2],"reported":[3],"promising":[4],"efficacy":[5,61],"for":[6,12,73,97,115,133,171,233,355,458],"venetoclax":[7,57],"(V)":[8],"plus":[9],"da-R-EPOCH":[10],"(VR-EPOCH)":[11],"26":[13],"patients":[14],"(pts)":[15],"with":[16,23,67,108,113,122,148,178,280,342],"CLL":[17,109,215,344,356],"who":[18],"developed":[19],"Richter":[20],"Syndrome":[21],"(RS),":[22],"a":[24,88,370],"CR":[25],"rate":[26],"of":[27,32,81,95,145,186,237,267,287,373,407],"50%":[28],"and":[29,37,110,224,273,327,350,442,469,483,508,628],"median":[30,371,378,385],"OS":[31,386],"19.6":[33],"mo.;":[34],"however,":[35],"hematologic":[36],"infectious":[38],"complications":[39],"were":[40,353],"common":[41],"(Davids":[42],"et":[43],"al.,":[44],"Blood,":[45],"2022).":[46],"hypothesized":[48],"that":[49],"de-intensifying":[50],"the":[51,56,64,74,298,303,411],"chemoimmunotherapy":[52],"backbone":[53],"while":[54,62],"keeping":[55],"could":[58,153],"potentially":[59],"preserve":[60],"mitigating":[63],"toxicities":[65,264],"observed":[66],"this":[68,243],"approach.":[69],"Here,":[70],"we":[71],"report":[72],"first":[75,299],"time":[76],"on":[77,291],"an":[78],"ongoing":[79,244],"study":[80,170,194,245],"VR-CHOP":[82,96,131,238],"in":[83,162,242,265,363],"RS.":[84,234],"Methods:":[85],"This":[86],"is":[87,246,380,387],"single-arm,":[89],"phase":[90],"2,":[91],"investigator":[92],"sponsored":[93],"trial":[94],"RS":[98],"(NCT03054896)":[99],"open":[100],"at":[101,359],"3":[102,251,263,328],"US":[103],"sites.":[104],"treated":[106],"pts":[107,191,228,268,290,314,341,362],"biopsy-confirmed":[111],"DLBCL":[112],"R-CHOP":[114],"1":[116,218,285,338],"cycle,":[117],"then":[118,130,154],"after":[119,284],"count":[120],"recovery":[121],"accelerated":[123],"inpatient":[124],"daily":[125,156,281],"V":[126,157,282],"ramp-up":[127,283],"(20/50/100/200/400":[128],"mg),":[129],"outpatient":[132],"up":[134],"to":[135,167,240,319,324,330,367,410,471],"5":[136],"additional":[137],"21d":[138],"cycles":[139,164,239],"(V":[140],"400":[141,158],"mg":[142,159],"qd,":[143],"d1\u201310":[144],"each":[146],"cycle)":[147],"mandatory":[149],"G-CSF":[150],"support.":[151],"Responders":[152],"receive":[155],"qd":[160],"maintenance":[161],"28d":[163],"or":[165,205,417,490,516,578,613],"elect":[166],"come":[168],"off":[169],"alloHCT.":[172,368],"Response":[173],"was":[174,217,394],"by":[175,181,357],"Lugano":[176],"criteria":[177],"PET/CT,":[179],"toxicity":[180,253],"CTCAE":[182],"v4.03.":[183],"Results:":[184],"As":[185],"24":[187],"Feb":[188],"2023,":[189],"27":[190],"have":[192,294,315],"started":[193],"treatment.":[195],"Median":[196,212,235],"age:":[197],"72":[198],"yrs":[199],"(range":[200,219,248,376],"42\u201380),":[201],"37%":[202],"had":[203,209,230,347],"del(17p)":[204],"TP53":[206],"mut,":[207],"26%":[208],"NOTCH1":[210],"mut.":[211],"#":[213,236],"prior":[214,231,323],"treatments":[216],"1\u20139),":[220],"including":[221],"44%":[222],"post-BTKi":[223],"17%":[225],"post-V;":[226],"4":[227,247,317],"(15%)":[229],"treatment":[232,293],"date":[241],"1\u20136).":[249],"\u2265Gr":[250,262],"heme":[252],"included:":[254,269],"neutropenia":[255,271],"(36%),":[256],"anemia":[257],"(32%),":[258],"thrombocytopenia":[259],"(40%).":[260],"Additional":[261],"\u226510%":[266],"febrile":[270],"(32%)":[272],"peripheral":[274],"neuropathy":[275],"(12%).":[276],"No":[277],"TLS":[278],"occurred":[279],"cycle":[286],"R-CHOP.":[288],"Two":[289],"active":[292],"not":[295],"yet":[296],"reached":[297],"response":[300],"eval.":[301],"In":[302],"remaining":[304],"25":[305],"pts,":[306],"ORR:":[307],"68%":[308],"(17/25),":[309],"CR:":[310],"48%":[311],"(12/25).":[312],"7":[313,361],"died:":[316],"due":[318,329],"PD":[320],"(including":[321],"2":[322,334],"starting":[325],"V)":[326],"infection":[331],"(n":[332],"=":[333,337],"sepsis,":[335],"n":[336],"COVID-19).":[339],"8":[340],"initial":[343],"marrow":[345],"involvement":[346],"re-staging":[348],"marrows,":[349],"88%":[351],"(7/8)":[352],"uMRD":[354],"flow":[358],"10\u20134.":[360],"remission":[364],"electively":[365],"went":[366],"With":[369],"follow-up":[372],"6.1":[374],"mo":[375,382,389],"0.1\u201321.4),":[377],"PFS":[379],"7.2":[381],"(Figure":[383,390],"A),":[384],"19.5":[388],"B).":[391],"The":[392],"research":[393],"funded":[395],"by:":[396],"Genentech":[397,622],"Keywords:":[398],"Chemotherapy,":[399],"Chronic":[400],"Lymphocytic":[401],"Leukemia":[402],"(CLL),":[403],"Combination":[404],"Therapies":[405],"Conflicts":[406],"interests":[408],"pertinent":[409],"abstract.":[412],"M.":[413],"S.":[414],"Davids":[415],"Consultant":[416,489,515,577,612],"advisory":[418,491,517,579,614],"role:":[419,492,518,580,615],"AbbVie,":[420,475,493,506,521,541,617,625],"Adaptive":[421,525,549,618,629],"Biotechnologies,":[422,526,550,619],"Ascentage":[423,476],"Pharma,":[424,477,533,594,606],"AstraZeneca,":[425,478,494,501,523,543],"BeiGene,":[426,583,601],"Bristol-Myers":[427],"Squibb,":[428],"Eli":[429],"Lilly,":[430,621],"Genentech,":[431,479,495,505,522,542],"Genmab,":[432],"Janssen,":[433,497,507,520,590,616],"Merck,":[434],"Mingsight":[435],"Pharmaceuticals,":[436,438],"Ono":[437],"Secura":[439,481],"Bio,":[440,482],"Takeda,":[441,557],"TG":[443,484,607],"Therapeutics":[444,485,608],"Honoraria:":[445,500],"Aptitude":[446],"Health,":[447],"AXIS":[448],"Medical":[449,459],"Education,":[450,455,460,466],"BioAscend,":[451],"Curio":[452],"Science,":[453],"Medscape":[454],"PeerView":[456],"Institute":[457],"Physician's":[461],"Education":[462],"Resource,":[463],"PlatformQ":[464],"Health":[465],"Plexus":[467],"Communications,":[468],"Research":[470,473,503,538,599,623],"Practice":[472],"funding:":[474,504,539,600,624],"Novartis,":[480,567],"K.":[486],"A.":[487,610],"Rogers":[488],"Pharmacyclics,":[496,519,540,626],"Beigene,":[498,530,620],"LOXO/Lilly":[499],"Janssen":[502],"Novartis":[509],"Educational":[510],"grants:":[511],"AstraZeneca":[512],"N.":[513],"Jain":[514],"BMS,":[524,544],"Kite/Gilead,":[527,555],"Precision":[528,551],"Biosciences,":[529,552,569],"Cellectis,":[531,548],"MEI":[532,593,605],"Ipsen,":[534],"CareDX,":[535],"MingSight,":[536],"Novalgen":[537],"Pfizer,":[545,597],"ADC":[546],"Therapeutics,":[547,554,563,596],"Fate":[553],"Mingsight,":[556],"Medisix,":[558],"Loxo":[559],"Oncology,":[560],"Novalgen,":[561],"Dialectic":[562],"Newave,":[564],"TransThera":[565],"Sciences,":[566],"Carna":[568],"Sana":[570],"Biotechnology,":[571],"Kisoji":[572],"Biotechnology":[573],"J.":[574],"R.":[575],"Brown":[576],"Abbvie,":[581],"Acerta/Astra-Zeneca,":[582],"Genentech/Roche,":[584],"Grifols":[585],"Worldwide":[586],"Operations,":[587],"Hutchmed,":[588],"iOnctura,":[589,603],"Kite,":[591],"Loxo/Lilly,":[592,604],"Numab":[595],"Pharmacyclics":[598],"Gilead,":[602],"P.":[609],"Thompson":[611],"Lilly":[627],"Biotechnologies":[630]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":9},{"year":2024,"cited_by_count":11},{"year":2023,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-06-10T00:00:00"}